mResvia

News

Moderna's mResvia gets shot in the arm from EU contract

A new EU procurement contract could give Moderna's RSV shot mResvia, which has struggled to gain traction in the market, a welcome boost.

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

Stéphane Bancel, Moderna's chief executive

Moderna's RSV shot gets US nod for use in younger adults

The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?

News

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

GSK gets EU okay for RSV shot in younger age group

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could l

Moderna's mResvia gets shot in the arm from EU contract

GSK's RSV shot cleared in US for all adults

Moderna's RSV shot gets US nod for use in younger adults

GSK rides out vaccine sales weakness with cancer, HIV gains

11 blockbuster drugs to look out for in 2025

GSK gets EU okay for RSV shot in younger age group

UK's Mission divests kidney drug to Dimerix for $292m

Discover a new era of healthcare panel engagement: Grounded ...

mResvia

Editor's Picks